vs

Side-by-side financial comparison of CISO Global, Inc. (CISO) and Lineage Cell Therapeutics, Inc. (LCTX). Click either name above to swap in a different company.

Lineage Cell Therapeutics, Inc. is the larger business by last-quarter revenue ($6.6M vs $6.3M, roughly 1.1× CISO Global, Inc.). Lineage Cell Therapeutics, Inc. runs the higher net margin — 12.9% vs -35.4%, a 48.2% gap on every dollar of revenue. On growth, Lineage Cell Therapeutics, Inc. posted the faster year-over-year revenue change (130.4% vs -15.4%). Over the past eight quarters, Lineage Cell Therapeutics, Inc.'s revenue compounded faster (113.9% CAGR vs -11.6%).

CISO Global, Inc. is a specialized cybersecurity services provider. It offers managed security monitoring, risk assessment, compliance advisory and incident response, serving North American SMEs, government and commercial clients across healthcare, retail and finance to help safeguard digital assets and mitigate cyber risks.

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to eithe...

CISO vs LCTX — Head-to-Head

Bigger by revenue
LCTX
LCTX
1.1× larger
LCTX
$6.6M
$6.3M
CISO
Growing faster (revenue YoY)
LCTX
LCTX
+145.8% gap
LCTX
130.4%
-15.4%
CISO
Higher net margin
LCTX
LCTX
48.2% more per $
LCTX
12.9%
-35.4%
CISO
Faster 2-yr revenue CAGR
LCTX
LCTX
Annualised
LCTX
113.9%
-11.6%
CISO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CISO
CISO
LCTX
LCTX
Revenue
$6.3M
$6.6M
Net Profit
$-2.2M
$851.0K
Gross Margin
28.6%
Operating Margin
-33.7%
-99.1%
Net Margin
-35.4%
12.9%
Revenue YoY
-15.4%
130.4%
Net Profit YoY
59.8%
126.0%
EPS (diluted)
$0.10
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CISO
CISO
LCTX
LCTX
Q4 25
$6.3M
$6.6M
Q3 25
$6.5M
$3.7M
Q2 25
$6.7M
$2.8M
Q1 25
$7.2M
$1.5M
Q4 24
$7.4M
$2.9M
Q3 24
$7.5M
$3.8M
Q2 24
$7.8M
$1.4M
Q1 24
$8.0M
$1.4M
Net Profit
CISO
CISO
LCTX
LCTX
Q4 25
$-2.2M
$851.0K
Q3 25
$2.5M
$-29.8M
Q2 25
$-3.0M
$-30.5M
Q1 25
$-5.4M
$-4.1M
Q4 24
$-5.5M
$-3.3M
Q3 24
$-3.7M
$-3.0M
Q2 24
$-8.4M
$-5.8M
Q1 24
$-6.6M
$-6.5M
Gross Margin
CISO
CISO
LCTX
LCTX
Q4 25
28.6%
Q3 25
24.9%
Q2 25
24.4%
Q1 25
24.9%
97.6%
Q4 24
24.8%
94.6%
Q3 24
13.8%
99.0%
Q2 24
12.0%
96.9%
Q1 24
8.8%
93.2%
Operating Margin
CISO
CISO
LCTX
LCTX
Q4 25
-33.7%
-99.1%
Q3 25
-40.8%
-102.9%
Q2 25
-34.7%
-715.4%
Q1 25
-23.9%
-433.1%
Q4 24
-26.1%
-178.2%
Q3 24
-46.8%
-101.6%
Q2 24
-54.3%
-416.7%
Q1 24
-61.0%
-461.3%
Net Margin
CISO
CISO
LCTX
LCTX
Q4 25
-35.4%
12.9%
Q3 25
39.2%
-809.0%
Q2 25
-44.8%
-1101.8%
Q1 25
-75.1%
-275.6%
Q4 24
-74.5%
-114.1%
Q3 24
-49.0%
-80.3%
Q2 24
-108.0%
-409.1%
Q1 24
-82.4%
-453.0%
EPS (diluted)
CISO
CISO
LCTX
LCTX
Q4 25
$0.10
$0.00
Q3 25
$-0.05
$-0.13
Q2 25
$-0.09
$-0.13
Q1 25
$-0.38
$-0.02
Q4 24
$-0.47
$0.00
Q3 24
$-0.32
$-0.02
Q2 24
$-0.69
$-0.03
Q1 24
$-0.55
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CISO
CISO
LCTX
LCTX
Cash + ST InvestmentsLiquidity on hand
$1.7M
$55.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$14.8M
$44.5M
Total Assets
$25.0M
$112.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CISO
CISO
LCTX
LCTX
Q4 25
$1.7M
$55.8M
Q3 25
$1.1M
$40.5M
Q2 25
$760.8K
$42.3M
Q1 25
$1.8M
$47.9M
Q4 24
$992.6K
$47.8M
Q3 24
$443.1K
$32.7M
Q2 24
$1.1M
$38.5M
Q1 24
$1.5M
$43.6M
Total Debt
CISO
CISO
LCTX
LCTX
Q4 25
Q3 25
$2.1M
Q2 25
$9.9M
Q1 25
$10.6M
Q4 24
$11.7M
Q3 24
$11.9M
Q2 24
$12.8M
Q1 24
$15.1M
Stockholders' Equity
CISO
CISO
LCTX
LCTX
Q4 25
$14.8M
$44.5M
Q3 25
$16.3M
$22.0M
Q2 25
$7.6M
$48.4M
Q1 25
$7.0M
$79.0M
Q4 24
$1.1M
$78.4M
Q3 24
$3.0M
$66.2M
Q2 24
$5.6M
$68.3M
Q1 24
$11.2M
$72.4M
Total Assets
CISO
CISO
LCTX
LCTX
Q4 25
$25.0M
$112.6M
Q3 25
$25.1M
$89.6M
Q2 25
$25.8M
$90.8M
Q1 25
$27.8M
$111.8M
Q4 24
$26.7M
$113.2M
Q3 24
$26.6M
$96.6M
Q2 24
$43.2M
$102.8M
Q1 24
$47.5M
$108.5M
Debt / Equity
CISO
CISO
LCTX
LCTX
Q4 25
Q3 25
0.13×
Q2 25
1.31×
Q1 25
1.52×
Q4 24
10.20×
Q3 24
3.92×
Q2 24
2.27×
Q1 24
1.35×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CISO
CISO
LCTX
LCTX
Operating Cash FlowLast quarter
$-1.8M
$-4.9M
Free Cash FlowOCF − Capex
$-5.3M
FCF MarginFCF / Revenue
-79.9%
Capex IntensityCapex / Revenue
6.0%
Cash ConversionOCF / Net Profit
-5.73×
TTM Free Cash FlowTrailing 4 quarters
$-19.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CISO
CISO
LCTX
LCTX
Q4 25
$-1.8M
$-4.9M
Q3 25
$-876.7K
$-3.6M
Q2 25
$-2.3M
$-5.5M
Q1 25
$-3.0M
$-4.9M
Q4 24
$-259.0K
$-6.3M
Q3 24
$-903.1K
$-5.8M
Q2 24
$-1.3M
$-5.2M
Q1 24
$-1.4M
$-5.8M
Free Cash Flow
CISO
CISO
LCTX
LCTX
Q4 25
$-5.3M
Q3 25
$-3.6M
Q2 25
$-5.6M
Q1 25
$-5.0M
Q4 24
$-6.7M
Q3 24
$-5.9M
Q2 24
$-1.3M
$-5.2M
Q1 24
$-1.5M
$-5.8M
FCF Margin
CISO
CISO
LCTX
LCTX
Q4 25
-79.9%
Q3 25
-98.6%
Q2 25
-200.8%
Q1 25
-331.8%
Q4 24
-234.0%
Q3 24
-156.1%
Q2 24
-16.4%
-371.2%
Q1 24
-18.5%
-403.1%
Capex Intensity
CISO
CISO
LCTX
LCTX
Q4 25
6.0%
Q3 25
0.3%
Q2 25
0.5%
Q1 25
6.5%
Q4 24
0.0%
12.7%
Q3 24
0.0%
3.0%
Q2 24
0.1%
3.6%
Q1 24
0.9%
2.6%
Cash Conversion
CISO
CISO
LCTX
LCTX
Q4 25
-5.73×
Q3 25
-0.35×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CISO
CISO

Security Managed Services$5.4M87%
Other$823.3K13%

LCTX
LCTX

Collaboration Revenues$6.3M95%
Other$345.0K5%

Related Comparisons